UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 30, 2022
TRxADE HEALTH, INC.
(Exact name of Registrant as specified in its charter)
Delaware | 001-39199 | 46-3673928 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
2420 Brunello Trace Lutz, Florida |
33558 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 800-261-0281
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.00001 Par Value Per Share |
MEDS | The NASDAQ Stock Market LLC (Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Resignation of Howard A. Doss as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
On March 30, 2022, Howard A. Doss provided notice to the Board of Directors of TRxADE HEALTH, Inc. (the “Company”, “we” and “us”) that he was resigning as Chief Financial Officer (CFO), and consequently, as Principal Financial Officer and Principal Accounting Officer, of the Company effective as of April 2, 2022. Mr. Doss who has been employed as CFO since January 2014, is resigning to spend time with his family and pursue other business opportunities.
(c) Appointment of Janet Huffman as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
On March 31, 2022, the Board of Directors approved the appointment of Ms. Janet Huffman, the Company’s Director of Finance (a non-executive position), as CFO and Principal Financial/Accounting Officer of the Company, effective April 2, 2022, upon effectiveness of Mr. Doss’ resignation.
Ms. Huffman is not party to any material plan, contract or arrangement (whether or not written) with the Company and there are no arrangements or understandings between Ms. Huffman and any other person pursuant to which she was selected to serve as an officer of the Company, nor is she a participant in any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K, except in connection with the Offer Letter, Non-Competition and Confidentiality Agreement and Mutual Nondisclosure Agreement, as discussed below.
Ms. Huffman’s biographical information is included below:
Ms. Huffman, age 50, joined the Company as Director of Finance in February 2022. Ms Huffman has served in various finance roles within the healthcare industry. In 2009, Ms. Huffman joined Infinity Home Care and served as Director of Finance and Regional Director of Operations until 2013. From 2013 to 2014, Ms. Huffman served as Director of Finance for Internal Medicine Associates and from 2014 to 2016, she served as Vice President of Finance for Family Home Health Services. Inc. Starting in February 2017 and continuing through January of 2020, Ms. Huffman served as the CFO for Signature Home Now, a Kentucky based healthcare company, in her role as CFO Ms. Huffman supported the home health division providing financial and operational direction. In January of 2019, Ms. Huffman became one of the founders of Banyan Pediatric Care Centers, Inc serving as its CFO; in 2021 Ms. Huffman led Banyan through a merger with Arboreta Healthcare Inc. continuing as its CFO until February of 2022. She obtained a Bachelor of Arts degree in accounting from the University of South Florida.
On February 3, 2022, the Company, through its wholly-owned subsidiary, Trxade, Inc., entered into an offer letter with Ms. Huffman (the “Offer Letter”), pursuant to which she agreed to become employed as the Director of Finance of Trxade, Inc. The Offer Letter provides for Ms. Huffman to be paid an annual salary of $175,000 per year, increasing to $225,000 in the event that she transitioned to the role of CFO (which transition is effective April 2, 2022). The Offer Letter also provides that she is eligible for yearly discretionary bonuses in cash, stock or equity, in an amount determined in the discretion of the Board of Directors, and may also be eligible for performance bonuses based on Ms. Huffman’s individual performance, without any specific criteria or metrics. If Ms. Huffman leaves Trxade, Inc. within 12 months of the date of employment, Trxade, Inc. agreed to pay her up to $3,000 in COBRA assistance and Trxade, Inc. agreed to pay her up to $10,000 of relocation expenses, which are repayable to Trxade, Inc. if she leaves on her own within 12 months of the date of engagement. Ms. Huffman is eligible to participate in all of Trxade, Inc.’s health, dental, vision and insurance plans, upon completion of 60 days of service. Ms. Huffman also signed the Company’s standard non-compete and confidentiality agreement, providing for a two year non-solicitation and non-compete obligation (prohibiting competition in connection with any business or enterprise that is similar to Trxade, Inc.’s and located or operated in the U.S. or any other country in which Trxade, Inc. does business prior to such termination) following the termination of her employment with Trxade, Inc., and customary confidentiality obligations, and Trxade, Inc.’s standard mutual nondisclosure agreement, in connection with her engagement.
Separate from the Offer Letter, Mr. Huffman is eligible to receive discretionary bonuses, in cash, stock or other equity compensation, from time to time, in the discretion of the Board of Directors or Compensation Committee of the Company. Additionally, her salary may also be increased from time to time, with or without amending her Offer Letter, by the Board of Directors or Compensation Committee of the Company.
The foregoing summary of the material terms of the Offer Letter, Non-Competition and Confidentiality Agreement and Mutual Nondisclosure Agreement, is not complete and is qualified in its entirety by reference to the Offer Letter, Form of Non-Competition and Confidentiality Agreement and Form of Mutual Nondisclosure Agreement, copies of which are filed herewith as Exhibits 10.1, 10.2 and 10.3, respectively, and incorporated by reference in this Item 5.02, in their entirety.
There are no family relationships between any director or executive officer of the Company, including, but not limited to Ms. Huffman.
Exhibit No. |
Description | |
10.1* | Offer Letter dated February 3, 2022, between Trxade, Inc. and Janet Huffman | |
10.2* | Form of Non-Competition and Confidentiality Agreement (Trxade, Inc.) | |
10.3* | Form of Mutual Nondisclosure Agreement (Trxade, Inc.) | |
104 | Inline XBRL for the cover page of this Current Report on Form 8-K |
* Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRXADE HEALTH, INC. | ||
Date: April 1, 2022 | By: | /s/ Suren Ajjarapu |
Name: | Suren Ajjarapu | |
Title: | Chief Executive Officer |
Exhibit 10.1
![]() |
2420 Brunello Trace, Lutz, FL -33558 * PH: 800-261-0281 * FAX: 800-265-6932 * www.Trxadehealth.com |
February 3rd, 2022
Ms. Janet Huffman Sarasota, FL
Dear Ms. Huffman,
We are pleased to extend an offer of employment with Trxade, Inc., a subsidiary of TRxADE HEALTH, INC. This employment offer is contingent upon successful completion of a background check, online personality test and pre-employment drug test conducted in accordance with applicable federal, state and local laws. Upon your acceptance of this employment offer our Human Resources Department will contact you to complete all the necessary forms and instructions.
The following details summarize the offer of employment:
1. | Full-time employment as Director of Finance |
2. | Effective Start date is February 14th, 2022 |
3. | Annual Base Salary of $175,000 per year paid as per company by weekly payroll process. |
4. | Upon transition to the Chief Financial Officer position: (Anticipated transition Date: May 15th, 2022 or sooner after 1Q 10Q is filed ) |
a. | Annual Base Salary of $225,000 per year | |
b. | Discretionary Bonus – Executive shall be eligible for a yearly discretionary cash, stock, or equity bonus equal to an amount as determined by the Board and based on the condition of the Company’s business and results of operations, and the Board’s evaluation of the Executive’s individual performance for the relevant period and/or such other matters as the Board in their discretion may deem relevant. Each Discretionary Bonus shall be paid at the Board’s discretion. |
5. | Cobra payment assistance up to $3000 if Ms. Huffman leaves on her own with in 12 months of employment this amount will be paid back to company |
6. | Relocation assistance up to $10,000 if Ms. Huffman leaves on her own with in 12 months of employment this amount will be paid back to company. |
Acceptance of this offer acknowledges that the Company is an at-will employer, and that this means that the company may terminate the employment agreement at any time, for any reason, with or without cause or notice and in accordance with applicable law. No officer, employee or representative of the company is authorized to enter an agreement-express or implied-with any employee for employment for a specified period. Any agreement for employment for a specific period will be put into writing and signed by an authorized party of the company. Employment is conditional on a 90-day probationary period. Please refer to TRxADE Employment Handbook for additional terms and conditions of employment.
You will be eligible for health, dental, vision and life insurance upon completion of 60 days after the first month of employment. You will be eligible for the 401(k) plan after 365 days of employment. Under the Immigration Reform and Control Act (IRCA), our company is required to verify the identity and work authorization of all newly hired employees. Therefore, if you accept this position, you will be required to complete a Form I-9 upon hire. Within three business days of beginning employment, you will need to supply acceptable documentation of your identity and work authorization.
In addition, you will be required to sign our non-compete and confidentiality agreement before you may begin employment with our company.
This offer of employment is valid until February 4th, 2022, at 5PM EST.
If you accept this offer of employment, you will begin work as soon as drug screening, background and personality test results have been completed, with an official hire date of February 14th, 2022, and will receive your first paycheck as per company policy, with appropriate payroll deductions as required by law. Payroll is paid biweekly, with one week to accommodate payroll processing.
To confirm your acceptance, please sign and return a copy of this letter. We look forward to having you as a member of our executive team.
Sincerely, | |
|
|
Suren Ajjarapu | |
Chief Executive Officer |
Agreed and accepted on February 3, 2022 | |
/s/ Janet Huffman 2/3/22 | |
Janet Huffman |
Exhibit 10.2
FORM OF
NON-COMPETITION AND CONFIDENTIALITY AGREEMENT
THIS AGREEMENT (the “Agreement) is made and entered into this ____ day of _________ by and between TRXADE HEALTH, INC., a Florida corporation. (called “TRxADE” or “the Company”), and __________ (called “Employee”). TRxADE and Employee may together be referred to as “Parties’ or each as a “Party”.
BACKGROUND
The Company is engaged in the business of running and operating an online pharmaceutical marketplace that allows independent pharmacists to save money by comparing prices and purchasing pharmaceuticals directly from providers. This includes obtaining the pricing information from providers and recruiting Independent Pharmacists to use the online marketplace as well as other related activities (“Business”).
The Company has significant expertise in its Business and has developed and maintains significant confidential information, good will and relationships with its employees and Business Associates (defined below):
The Company relies heavily on well-trained Employees, the development of good will, and maintaining of Business Associate and employee relationships.
The Company’s value and ability to compete absolutely depends on its ability to maintain long-term relationships with its Business Associates and employees, and to maintain the confidentiality of its Confidential Information. The Company invests significant resources in the development of relationships with Business Associates, its employees, its trade secrets, its confidential business information, and in specialized training for employees. The Company has a legitimate business interest in protecting its investment.
The parties want to work together (or continue working together), and the Company requires this Agreement as part of that employment relationship. Employee’s at-will employment as an employee or independent contractor is sufficient consideration for this Agreement.
Through employment with the Company, Employee has access to Company Assets. Company Assets include: (i) trade secrets, (ii) valuable confidential business or professional information, including methods of operation, (iii) names and other information concerning prospective or existing customers, referral sources, suppliers, agents, independent contractors and other parties with which the Company does business (which will cumulatively be referred to as “Business Associates”), (iv) the goodwill of the Company’s customers, referral sources, contractors and other Business Associates, (v) extraordinary or specialized training or education, (vi) other Confidential Information (defined below); and (vii) Company Employees.
Employee acknowledges the Company’s right and need to protect Company Assets, Employee understands that TRxADE is employing or continuing to employ him or her in reliance on Employee’s promises in this Agreement.
SPECIFIC TERMS
Therefore, the Parties hereby agree that the above statements are true and incorporated in this Agreement. This Agreement is made between TRxADE and Employee as a condition of employment.
TRxADE and Employee further agree as follows:
1. | Loyalty During Employment. Employee agrees that during employment with the Company, Employee owes a duty of loyalty to the Company. During employment, Employee will act in the best interest of the Company and will not take action which is harmful to the Company. |
2. | Terms of Agreement. Employee understands and agrees that this Agreement is fair and reasonable. This Agreement is independent of any other agreements and applies regardless of the reason that Employee and the Company may end their relationship. |
3. | Non-Solicitation of Employees. During employment with the Company and for the two year period following employment with the Company, Employee will not directly or indirectly encourage or solicit any Company Employee to leave the Company or change his or her employment relationship with the Company. Employee will not engage in these actions directly or indirectly and will not do so individually or in any capacity (such as for any company, partnership or otherwise). “Company Employee” means anyone who worked at the Company when Employee worked at the Company or during the two years following Employee’s separation from employment. |
4. | Non-Solicitation of Business Associates. During employment with the Company and for the two year period following employment, with the Company, Employee will not directly or indirectly solicit any Company Business Associates, including customers, for any business reason. Employee will not engage in these actions directly or indirectly and will not do so individually or in any capacity (such as for any company, partnership or otherwise). Company Business Associates are defined above. Employee agrees that, even after the two year period following separation from employment, Employee will never use the Company’s customer lists, information, or property. |
5. | Non-Competition. During the term hereof and for a period of two years immediately following employment, Employee shall not, directly or indirectly, for itself or on behalf of or in conjunction with any other person or entity, own, control, operate, be employed by, engage in, participate in, or have any interest in, the operation of any business or enterprise which is the same or similar to that of TRxADE, and which is located or operating in the United States of America, or any other country in which Company does business prior to the termination of employment. |
6. | Confidentiality. Employee has access to Confidential Information and agrees to keep that information confidential. Confidential Information can be in any form and includes Company-related financial information, employee information, legal matters, business operations, marketing and sales strategy and actions, customer and referral information, technical know-how, and other business information. Confidential Information includes any information learned by Employee through employment which relates to the Company and which the Company has not authorized be released to the general public. The Company may identify additional Confidential Information through policies, memos, or otherwise. |
7. | Company Property. All documents, information, and intellectual property purchased, possessed or created by any employee of the Company (including Employee), during employment and relating to the Company’s Business are owned by and shall be controlled by the Company. Upon separation from employment with the Company, Employee will immediately stop using all Company property and will return all copies to the Company. |
8. | Enforcement. Each provision of this Agreement shall be read as broadly as permitted by law, and if the law would require that any provision be restricted for any reason, it is the Parties’ desire that the Agreement otherwise be enforced to the extent permitted by law, |
9. | Remedies. The terms of this Agreement are of such a nature that in the event of a threatened or actual violation, proof of damages Would be extremely difficult, therefore the Company would be entitled to an injunction as well as damages. |
10. | Attorneys’ Fees. In the event of litigation to enforce this Agreement, the prevailing party shall recover from the breaching party all related costs, expenses and reasonable attorneys’ fees incurred through trial, appeal or appearance in federal bankruptcy or reorganization proceedings, and in connection with enforcing or collecting upon any final judgment. |
11. | Notice. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by certified or registered mail, return receipt requested, to the parties at the following address: |
To the Company at the Company’s main office and labeled “Attention: CEO” To
Employee: At the most recent home address on file with the Company.
12. | Waiver of Breach. The Company’s waiver of any breach or condition of this Agreement (by Employee or any other person) is not a waiver by the Company of any other breach. |
13. | Entire Agreement. This Agreement contains the entire agreement of the Parties, It may not be changed orally, but only by an agreement in writing signed by the parties hereto. |
14. | Governing Law and Venue. This Agreement shall be construed under and governed by the internal substantive laws of the State of Florida without regard to its conflict of laws provisions and venue shall lie in Pasco County. |
15. | Assignment. The Company shall have the right to assign all rights and interests in this Agreement. Such assignment of rights and interests would likely follow a merger, acquisition, sale or assets or other transfer of any aspect of business operations of Company.Employee hereby consents to assignment by Company. In the event of assignment by Company, the new entity shall be added to the Company throughout this Agreement, shall receive all of the rights, privileges and protections afforded the Company under this Agreement, and shall have the right to enforce it. This Agreement is personal to the Employee, who may not assign his or her rights or delegate his or her duties hereunder. |
The Parties agree to the above.
Employee | ||||
By: | Witness as to Employee:_______________________ | |||
TRXADE HEALTH, INC. | ||||
By: | ||||
Date: | __________________________ | |||
As its [Title of signing Party] |
Exhibit 10.3
FORM OF
TRXADE HEALTH, INC.
MUTUAL NONDISCLOSURE AGREEMENT
This Mutual Nondisclosure Agreement (this “Agreement”) is made as of __________, by and between Trxade Health, Inc., a Delaware corporation (the “Company”), and ______________ (“Counterparty”). Each party has disclosed and/or may further disclose its Confidential Information (as defined below) to the other in connection with the Relationship (as defined below) pursuant to the terms and conditions of this Agreement. As used herein, the term “Discloser” shall refer to the Company whenever the context refers to the Company’s Confidential Information being disclosed to Counterparty, which is referred to as “Recipient” in that context. Conversely, the term “Discloser” shall refer to Counterparty whenever the context refers to Counterparty’s Confidential Information being disclosed to the Company, which is referred to as “Recipient” in that context.
RECITALS
The parties wish to explore a possible business opportunity of mutual interest regarding a potential business relationship and/or investment (the “Relationship”) in connection with which Discloser has disclosed and/or may further disclose its Confidential information (as defined below) to Recipient. This Agreement is intended to allow the parties to continue to discuss and evaluate the Relationship while protecting Discloser’s Confidential Information (including Confidential Information previously disclosed to Recipient) against unauthorized use or disclosure.
AGREEMENT
In consideration of the premises and mutual covenants herein, the parties hereby agree as follows:
1. Definition of Confidential Information. “Confidential Information” means information and physical material not generally known or available outside Discloser and information and physical material entrusted to Discloser in confidence by third parties. Confidential Information includes, without limitation: technical data, trade secrets, know-how, research, product or service ideas or plans, software codes and designs , algorithms, developments, inventions, patent applications, laboratory notebooks, processes, formulas, techniques, mask works, engineering designs and drawings, hardware configuration information, agreements with third parties, lists of, or information relating to, employees and consultants of the Discloser (including, but not limited to, the names, contact information, jobs, compensation, and expertise of such employees and consultants), lists of, or information relating to, suppliers and customers, price lists, pricing methodologies, cost data, market share data, marketing plans, licenses, contract information, business plans, financial forecasts, historical financial data, budgets or other business information disclosed by Discloser (whether by oral, written, graphic or machine-readable format), which Confidential Information is designated in writing to be confidential or proprietary, or if given orally, is confirmed in writing as having been disclosed as confidential or proprietary within a reasonable time (not to exceed thirty (30) days) after the oral disclosure, or which information would, under the circumstances, appear to a reasonable person to be confidential or proprietary. Notwithstanding any failure to so identify it, however, all of the Company’s customer lists and purchasing/selling information shall be Confidential Information of the Company.
2. Nondisclosure of Confidential Information. Recipient shall not use any Confidential Information disclosed to it by Discloser for its own use or for any purpose other than to carry out discussions concerning, and the undertaking of, the Relationship. Recipient shall not disclose or permit disclosure of any Confidential Information of Discloser to third parties or to employees of Recipient, other than directors, officers, employees, consultants and agents of Recipient who are required to have the information in order to carry out the discussions regarding the Relationship. Recipient shall take reasonable measures to protect the secrecy of and avoid disclosure or use of Confidential Information of Discloser in order to prevent it from falling into the public domain or the possession of persons other than those persons authorized under this Agreement to have any such information. Such measures shall include the degree of care that Recipient utilizes to protect its own Confidential Information of a similar nature. Recipient shall notify Discloser of any misuse, misappropriation or unauthorized disclosure of Confidential Information of Discloser which may come to Recipient’s attention.
3. Exceptions. Notwithstanding the above, Recipient shall not have liability to Discloser with regard to any Confidential Information that the Recipient can prove:
(a) was in the public domain at the time it was disclosed or has entered the public domain through no fault of Recipient;
(b) was known to Recipient, without restriction, at the time of disclosure, as demonstrated by files in existence at the time of disclosure;
(c) was independently developed by Recipient without any use of the Confidential Information, as demonstrated by files created at the time of such independent development;
(d) is disclosed generally to third parties by Discloser without restrictions similar to those contained in this Agreement;
(e) becomes known to Recipient, without restriction, from a source other than Discloser without breach of this Agreement by Recipient and otherwise not in violation of Discloser’s rights;
(f) is disclosed with the prior written approval of Discloser; or
(g) is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however, that Recipient shall provide prompt notice of such court order or requirement to Discloser to enable Discloser to seek a protective order or otherwise prevent or restrict such disclosure.
4. Return of Materials. Recipient shall, except as otherwise expressly authorized by Discloser, not make any copies or duplicates of any Confidential Information. Any materials or documents that have been furnished by Discloser to Recipient in connection with the Relationship shall be promptly returned by Recipient, accompanied by all copies of such documentation, within ten (10) days after (a) the Relationship has been rejected or concluded or (b) the written request of Discloser.
-2- |
5. No Rights Granted. Nothing in this Agreement shall be construed as granting any rights under any patent, copyright or other intellectual property right of Discloser, nor shall this Agreement grant Recipient any rights in or to Discloser’s Confidential Information other than the limited right to review such Confidential Information solely for the purpose of determining whether to enter into the Relationship. Nothing in this Agreement requires the disclosure of any Confidential Information, which shall be disclosed, if at all, solely at Discloser’s option. Nothing in this Agreement requires the Discloser to proceed with the Relationship or any transaction in connection with which the Confidential Information may be disclosed.
6. No Representations Made. Recipient acknowledges that neither Discloser, nor any of its representatives, in the course of providing the Confidential Information as contemplated hereunder, is making any representation or warranty (express or implied) as to the accuracy or completeness of any such information, and Recipient assumes full responsibility for all conclusions derived from such information. Recipient shall be entitled to, and shall, rely solely on representations and warranties made in a definitive agreement, if any, relating to the Relationship.
7. No Reverse Engineering. Recipient shall not modify, reverse engineer, decompile, create other works from or disassemble any software programs contained in the Confidential Information of Discloser unless permitted in writing by Discloser.
8. No Publicity. Neither party shall, without the prior consent of the other party, disclose to any other person the fact that Confidential Information of Discloser has been and /or may be disclosed under this Agreement, that discussions or negotiations are taking place between the parties, or any of the terms, conditions, status or other facts with respect thereto, except as required by law and then only with prior notice as soon as possible to the other party.
9. Notice of Compelled Disclosure. In the event that Recipient or any person to whom they or their representatives transmit or have transmitted Confidential Information become legally compelled (by oral questions, interrogatories, requests for information or documents, subpoenas, civil investigative demands or otherwise) to disclose any such Confidential Information, the Recipient shall provide the Discloser with prompt written notice so that the Discloser may seek a protective order or other appropriate remedy, or both, or waive compliance with the provisions of this Agreement. In the event that the Discloser is unable to obtain a protective order or other appropriate remedy, or if it so directs the Recipient, the Recipient shall furnish only that portion of the Confidential Information that the Recipient is advised by written opinion of its counsel is legally required to be furnished by it and shall exercise its reasonable best efforts to obtain reliable assurance that confidential treatment shall be accorded such Confidential Information.
10. Regulation FD. Recipient understands that Discloser’s Confidential Information as well as the existence of the discussions concerning the Relationship and the terms of the Relationship being contemplated by the parties may be deemed material non-public information and Recipient shall not trade in the stock of Discloser while Recipient is in possession of any material non-public information conveyed hereunder.
-3- |
11. Common Interest Agreement. To the extent that any Confidential Information provided or made available hereunder may include material subject to the attorney-client privilege, work product doctrine or any other applicable privilege concerning pending or threatened legal proceedings or governmental investigations, Recipient and Discloser understand and agree that they have a commonality of interest with respect to such matters and it is their desire, intention and mutual understanding that the sharing of such material is not intended to, and shall not, waive or diminish in any way the confidentiality of such material or its continued protection under the attorney-client privilege, work product doctrine or other applicable privilege. All Confidential Information provided or made available by Discloser that is entitled to protection under the attorney-client privilege, work product doctrine or other applicable privilege shall remain entitled to such protection under these privileges, this Agreement, and under the joint defense doctrine. Nothing in this Agreement obligates Discloser to reveal material subject to the attorney-client privilege, work product doctrine or any other applicable privilege.
12. Term. The foregoing commitments of each party shall survive any termination of the Relationship between the parties, and shall continue for a period terminating five (5) years from the date on which Confidential Information is last disclosed under this Agreement, except with respect to Confidential Information of the Discloser that constitutes a trade secret under applicable law, in which case, such obligations of Recipient shall continue until such Confidential Information becomes publicly known or made generally available through no action or inaction of the Recipient.
13. Independent Contractors. The parties are independent contractors, and nothing contained in this Agreement shall be construed to constitute the parties as partners, joint venturers, co-owners or otherwise as participants in a joint or common undertaking.
14. Remedies. Each party’s obligations set forth in this Agreement are necessary and reasonable in order to protect Discloser and its business. Due to the unique nature of Discloser’s Confidential Information, monetary damages may be inadequate to compensate Discloser for any breach by Recipient of its covenants and agreements set forth in this Agreement. Accordingly, the parties each agree and acknowledge that any such violation or threatened violation may cause irreparable injury to Discloser and , in addition to any other remedies that may be available, in law, in equity or otherwise, Discloser shall be entitled to obtain injunctive relief against the threatened breach of this Agreement or the continuation of any such breach by Recipient.
15. Miscellaneous.
(a) Governing Law; Jurisdiction. The validity, interpretation, construction and performance of this Agreement, and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the state of Florida, without giving effect to principles of conflicts of law. Each of the parties hereto consents to the exclusive jurisdiction and venue of the courts of the state courts located Hillsborough County, Florida and the federal courts located in the Middle District of Florida.
-4- |
(b) Entire Agreement. This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes all prior or contemporaneous discussions, understandings and agreements, whether oral or written, between them relating to the subject matter hereof.
(c) Amendments and Waivers. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of that provision as to that or any other instance.
(d) Successors and Assigns. Except as otherwise provided in this Agreement, this Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. The Company may assign any of its rights and obligations under this Agreement. No other party to this Agreement may assign, whether voluntarily or by operation of law, any of its rights and obligations under this Agreement, except with the prior written consent of the Company. Notwithstanding the foregoing, Confidential Information of Discloser may not be assigned without the prior written consent of Discloser, unless the assignee shall be the successor entity to the assignor upon the dissolution of the assignor in its present form.
(e) Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficient when delivered personally or by overnight courier or sent by email, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the signature page, at the most recent address set forth in the Company’s books and records.
(f) Severability. If one or more provisions of this Agreement are held to be_unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms.
(g) Construction. This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto.
(h) Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and all of which together shall constitute one and the same agreement.
-5- |
The parties have executed this Mutual Nondisclosure Agreement as of the date first above written.
THE COMPANY: | ||
TRXADE HEALTH, INC. | ||
By: | ||
(Signature) | ||
Name: | ||
Title: | ||
Address: | ||
Trxade Health, Inc. P.O.Box 1186 Land O’Lakes, Florida 34639 | ||
COUNTERPARTY: | ||
(PRINT NAME): | ||
By: | ||
(Signature) | ||
Name: | ||
Title: | ||
Address: | ||
Email: |
-6- |